Eli Lilly Strikes $2.75 Billion Deal for AI-Developed Drugs
Eli Lilly partners with Insilico Medicine in a massive $2.75 billion agreement to bring artificial intelligence-developed drugs to the global market. The deal highlights the growing role of generative AI in accelerating pharmaceutical discovery and development.
Eli Lilly signs a $2.75 billion deal with Hong Kong-based Insilico Medicine to bring AI-developed drugs to the global market. Under the agreement, Insilico receives $115 million upfront, with the remaining funds tied to regulatory and commercial milestones alongside future sales royalties. Insilico currently uses generative AI to develop at least 28 drugs, with nearly half already reaching the clinical stage.
The two companies build upon a software licensing agreement originally signed in 2023. As part of the expanded partnership, Insilico joins Lilly’s Gateway Labs community to collaborate on identifying promising therapeutic candidates across multiple disease areas. Insilico's CEO praises Lilly for successfully integrating biology, chemistry, and automation, calling the collaboration a powerful complement to Lilly's existing clinical development capabilities.
This partnership aligns with Eli Lilly's recent commitment to invest $3 billion in China over the next decade. While Insilico conducts its AI research outside of China in locations like Canada and the Middle East, the company handles early preclinical drug development within China. By leveraging artificial intelligence, Insilico significantly reduces research time and synthesizes molecules much faster than traditional drug discovery methods allow.